Vaccine startup Vaxart (NASDAQ: VXRT) announced Thursday morning that it was initiating a memorandum of understanding with Attwill Medical Solutions Sterilflow. The latter company will produce components for Vaxart's COVID-19 vaccine candidate currently in preclinical development, and Vaxart's stock exploded upward by more than 96% on the news.
The agreement between the two companies isn't finalized yet, and Vaxart's COVID-19 vaccine isn't even ready to enter early clinical trials despite the company moving to secure manufacturing resources. Nonetheless, biotech investors seeking gains from COVID-19 vaccine development might consider buying Vaxart now to position themselves for another round of wild growth.
Image source: Getty Images.